Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Crompton

Showing results (181-190 of 197) with videos related to

Pageof 20
Sort By:
Nature Communications|June 23, 2016
Integrated genetic and pharmacologic interrogation of rare cancersAndrew L Hong, Yuen-Yi Tseng, Glenn S Cowley, et al.
Science Translational Medicine|September 14, 2021
Bispecific antibodies targeting distinct regions of the spike protein potently neutralize SARS-CoV-2 variants of concernHyeseon Cho, Kristina Kay Gonzales-Wartz, Deli Huang, et al.
Nature Medicine|April 16, 2026
Trabectedin and low-dose irinotecan to target EWS::FLI1 in Ewing sarcoma: a phase 1/2 trialPatrick J Grohar, Rachel Heise, Mary Frances Wedekind, et al.
Cell|July 26, 2024
Natural malaria infection elicits rare but potent neutralizing antibodies to the blood-stage antigen RH5Lawrence T Wang, Andrew J R Cooper, Brendan Farrell, et al.
Biorxiv : the Preprint Server for Biology|April 6, 2021
Ultrapotent bispecific antibodies neutralize emerging SARS-CoV-2 variantsHyeseon Cho, Kristina Kay Gonzales-Wartz, Deli Huang, et al.
Science (New York, N.Y.)|July 20, 2022
Broadly neutralizing antibodies target the coronavirus fusion peptideCherrelle Dacon, Courtney Tucker, Linghang Peng, et al.
The New England Journal of Medicine|April 26, 2024
Subcutaneous Administration of a Monoclonal Antibody to Prevent MalariaKassoum Kayentao, Aissata Ongoiba, Anne C Preston, et al.
Biorxiv : the Preprint Server for Biology|April 20, 2022
Broadly neutralizing antibodies target the coronavirus fusion peptideCherrelle Dacon, Courtney Tucker, Linghang Peng, et al.
Communications Biology|April 8, 2024
Targeting TRIP13 in favorable histology Wilms tumor with nuclear export inhibitors synergizes with doxorubicinKaruna Mittal, Garrett W Cooper, Benjamin P Lee, et al.
Elife|March 13, 2019
Renal medullary carcinomas depend upon <i>SMARCB1</i> loss and are sensitive to proteasome inhibitionAndrew L Hong, Yuen-Yi Tseng, Jeremiah A Wala, et al.
Pageof 20

Showing results (181-190 of 197) with videos related to

Sort By:
Pageof 20
Nature Communications|June 23, 2016
Integrated genetic and pharmacologic interrogation of rare cancersAndrew L Hong, Yuen-Yi Tseng, Glenn S Cowley, et al.
Science Translational Medicine|September 14, 2021
Bispecific antibodies targeting distinct regions of the spike protein potently neutralize SARS-CoV-2 variants of concernHyeseon Cho, Kristina Kay Gonzales-Wartz, Deli Huang, et al.
Nature Medicine|April 16, 2026
Trabectedin and low-dose irinotecan to target EWS::FLI1 in Ewing sarcoma: a phase 1/2 trialPatrick J Grohar, Rachel Heise, Mary Frances Wedekind, et al.
Cell|July 26, 2024
Natural malaria infection elicits rare but potent neutralizing antibodies to the blood-stage antigen RH5Lawrence T Wang, Andrew J R Cooper, Brendan Farrell, et al.
Biorxiv : the Preprint Server for Biology|April 6, 2021
Ultrapotent bispecific antibodies neutralize emerging SARS-CoV-2 variantsHyeseon Cho, Kristina Kay Gonzales-Wartz, Deli Huang, et al.
Science (New York, N.Y.)|July 20, 2022
Broadly neutralizing antibodies target the coronavirus fusion peptideCherrelle Dacon, Courtney Tucker, Linghang Peng, et al.
The New England Journal of Medicine|April 26, 2024
Subcutaneous Administration of a Monoclonal Antibody to Prevent MalariaKassoum Kayentao, Aissata Ongoiba, Anne C Preston, et al.
Biorxiv : the Preprint Server for Biology|April 20, 2022
Broadly neutralizing antibodies target the coronavirus fusion peptideCherrelle Dacon, Courtney Tucker, Linghang Peng, et al.
Communications Biology|April 8, 2024
Targeting TRIP13 in favorable histology Wilms tumor with nuclear export inhibitors synergizes with doxorubicinKaruna Mittal, Garrett W Cooper, Benjamin P Lee, et al.
Elife|March 13, 2019
Renal medullary carcinomas depend upon <i>SMARCB1</i> loss and are sensitive to proteasome inhibitionAndrew L Hong, Yuen-Yi Tseng, Jeremiah A Wala, et al.
Pageof 20